A new UK start-up company, TopiVert, is set to receive £8 million in venture capital from the Imperial Innovations Group Plc and SV Life Sciences. TopiVert will develop topical drugs for inflammatory diseases of the eye and gut. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
